In this episode of WND focusing on breast cancer, Dr. Kevin Punie from GZA Hospitals and Prof. Evandro de Azambuja from Institut Jules Bordet will delve into two publications from the OlympiAD trial. This phase 3 trial assessed patients with

In this episode of WND in breast cancer, Dr Kevin Punie from GZA Hospitals and Prof Evandro de Azambuja from Institut Jules Bordet will focus on the recently published clinical practice guidelines from ESMO

In this episode of WND Breast, Dr Kevin Punie from GZA Hospitals and Prof Evandro de Azambuja from Institut Jules Bordet discuss the KEYNOTE-756 trial.
This global phase 3 trial, employing a double-blind, placebo-controlled design, investigated the efficacy of adding

This randomized, double-blind phase 3 trial focused on high-risk, ER+/HER2- primary breast cancer. Nivolumab and placebo were added to neoadjuvant chemotherapy, followed by adjuvant endocrine therapy with or without nivolumab for 1 year.
Newly diagnosed patients were selected based on

The TROPION-Breast01 study enrolled over 700 HR+/HER2- breast cancer patients who had experienced progression on endocrine therapy and had received one or two prior lines of chemotherapy. They were randomly assigned to either treatment with the Trop2-directed ADC datopotamab deruxtecan

While ADCs have shown efficacy in HER2+ disease, this trial focuses on HER2-low patients, characterized by low HER2 IHC scores of +1 or +2 with negative FISH tests. Despite their low HER2 levels, these tumours still present potential docking sites

In this episode of WND Breast, Dr. Kevin Punie from GZA Hospitals and Prof. Evandro de Azambuja from Institut Jules Bordet will discuss the updated findings of the PRECISION 2 trial. This tumour-agnostic open-label, single-arm phase 2 study was sponsored

In this episode of WND Breast, Dr Kevin Punie from GZA Hospitals and Prof Evandro de Azambuja from Institut Jules Bordet will discuss the updated findings of the KATHERINE trial.
The KATHERINE trial recently provided updated results from its phase

In this episode of WND Breast, Dr Kevin Punie from GZA Hospitals and Prof Evandro de Azambuja from Institut Jules Bordet will delve into the NATALEE trial, contributing insights to adjuvant CDK4/6 inhibitors in breast cancer patients.
The NATALEE trial

In this episode of WND Breast, Dr Kevin Punie of GZA Hospitals and Prof Evandro de Azambuja from Institut Jules Bordet focus on the advantages of adjuvant CDK4/6 inhibitors for patients at high risk of recurrence from HR+/HER2- breast cancer.<br

Professor Evandro de Azambuja from Institut Jules Bordet and Dr Kevin Punie from GZA Hospitals will discuss two important trials concerning immune checkpoint inhibitors in TNBC patients: the NeoTRIP trial and the Impassion030 trial. Both trials add to the expanding

KEYNOTE-522, a widely recognized phase 3 trial, has led to a paradigm shift in the management of high-risk early-stage TNBC. The trial incorporates pembrolizumab within the neoadjuvant platinum-based chemotherapy regimen. Following definitive surgery, patients underwent adjuvant pembrolizumab or placebo administration

The review article discussed systematically assesses the impact of ADCs in BC treatment. Presently, three ADCs are deployed in clinical settings: two targeting HER2 and one directed against Trop2.
These pharmaceutical agents leverage the Trojan horse principle. The core mechanism

Capecitabine constitutes a pivotal therapeutic agent for breast cancer patients, employed in both early and advanced stages of the disease. Given its recognized toxicity profile, the optimization of dosing strategies is imperative to ensure optimal adherence.
The X-7/7 trial, presented

At ASCO 2023, data were presented from a meta-analysis investigating ovarian function suppression (OFS) in early luminal breast cancer. Upon comprehensive analysis, the earlier findings from previous trials were substantiated: the addition of OFS to endocrine therapy effectively mitigates recurrence

The TROPiCS-02 trial represents an international, open-label, phase 3 investigation targeting patients with advanced hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer. This study specifically focuses on individuals with advanced luminal disease who exhibited progression

The DATA trial systematically explored the efficacy of extended adjuvant endocrine therapy utilizing anastrozole in patients with hormonal receptor-positive, predominantly HER2-negative breast cancer. Following a 2-3 year course of tamoxifen, patients were randomly allocated into two groups: one receiving an

The IMpassion 031 trial explored the potential benefits of neoadjuvant and adjuvant therapy involving atezolizumab for patients with stage 2 or stage 3 early-stage Triple Negative Breast Cancer (TNBC). Carlos Barrios presented the results of this small phase 3 trial

The SOFT trial investigates the impact of adding ovarian function suppression (OFS) to endocrine treatment with either tamoxifen or exemestane in premenopausal women with hormone receptor-positive breast cancer. Approximately 3,000 patients were assigned to one of three treatment groups: tamoxifen

The PALMIRA trial, a phase 2 open-label randomised study, sought answers to the pivotal question of whether continuing palbociclib beyond progression in metastatic breast cancer is clinically beneficial. Patients eligible for the trial exhibited disease progression after initial treatment with

Breast cancer treatment, particularly the use of anthracyclines, has long been a focus of study due to its association with cardiotoxicity. Oxford’s recent meta-analysis, scrutinising the efficacy of anthracyclines versus taxanes in approximately 18,000 patients, has sparked considerable debate within

The SONIA trial, a phase III study conducted by a Dutch academic group, focused on comparing first-line to second-line CDK4/6 inhibition in the treatment of endocrine-sensitive breast cancer. Recruiting over 1,000 patients in the Netherlands, the trial primarily investigated progression-free

The Phase III NATALEE trial assessed the impact of ribociclib (RIB) plus endocrine therapy (ET) on early breast cancer (EBC) outcomes, including a diverse group of stage II or III HR+/HER2− EBC patients). RIB was administered for 3 years at

The Phase III NATALEE trial assessed the impact of ribociclib (RIB) plus endocrine therapy (ET) on early breast cancer (EBC) outcomes, including a diverse group of stage II or III HR+/HER2− EBC patients). RIB was administered for 3 years at